EPIGENOMAX THERAPEUTICS LLC

EpiGenomax Therapeutics LLC specializes in advanced biomedical research and development services, with a focus on epigenetic analysis, genomic data interpretation, and translational therapeutics design. Leveraging cutting-edge molecular biology techniques, the company delivers precision science solutions for target identification, biomarker discovery, and epigenetic modulation strategies. Their technical expertise includes next-generation sequencing data analysis, chromatin immunoprecipitation workflows, DNA methylation profiling, and functional validation of epigenetic regulators in disease models. The firm differentiates itself through its integration of computational biology with wet-lab validation, enabling robust pipeline development for novel therapeutic candidates. While no award history is available to confirm specific client engagements, the company’s NAICS classification of 541714 indicates primary activity in biological research and development services, positioning it within the life sciences R&D sector. The entity operates as a small business under the 2K structure and is based in Woodbridge, Connecticut, with no publicly listed government certifications. Its market positioning reflects a niche focus on epigenomics-driven drug discovery, serving biopharmaceutical and government-funded research initiatives that require deep molecular insight and high-complexity data analysis. Without confirmed contract performance data, its agency relationships and institutional partnerships remain unverified, but its technical profile suggests alignment with NIH, CDC, and DOD biomedical research programs seeking advanced genomic capabilities.